Michael Giordano
Direktor/Vorstandsmitglied bei RAPT THERAPEUTICS, INC.
Vermögen: 36 117 $ am 30.04.2024
Aktive Positionen von Michael Giordano
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| RAPT THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2018 | - |
| Independent Dir/Board Member | 01.01.2018 | - | |
| ACHILLES THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 01.09.2018 | - |
| Independent Dir/Board Member | 01.09.2018 | - | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 19.09.2018 | - |
Oncovalent Therapeutics, Inc.
 Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Michael Giordano
Ehemalige bekannte Positionen von Michael Giordano
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EPIZYME, INC. | Direktor/Vorstandsmitglied | 01.08.2018 | 12.08.2022 |
| Technik-/Wissenschafts-/F&E-Leiter | 01.12.2017 | 01.08.2018 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.02.2012 | 01.02.2017 |
| Weill Cornell Medicine | Corporate Officer/Principal | - | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - | - |
Ausbildung von Michael Giordano
| The Johns Hopkins University | Undergraduate Degree |
| Weill Cornell Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Vereinigtes Königreich | 3 |
| 2 |
Operativ
| Director/Board Member | 5 |
| Corporate Officer/Principal | 3 |
| Independent Dir/Board Member | 2 |
Sektoral
| Health Technology | 7 |
| Consumer Services | 3 |
| Government | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
 | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Oncovalent Therapeutics, Inc.
Oncovalent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncovalent Therapeutics, Inc. develops immuno oncology drugs and therapeutics. The company is based in Thousand Oaks, CA. Pete Feldman has been the CEO of the company since 2020. | Health Technology |
- Börse
- Insiders
- Michael Giordano
- Erfahrung
